Publications by authors named "N Quiles-Tsimaratos"
Compared Burden of Psoriasis, Atopic Dermatitis, Hidradenitis Suppurativa, and Chronic Urticaria: Baseline Characteristics of the Patients Included in the OMCCI Cohort - A French, Prospective Multicenter Study of Chronic Inflammatory Dermatoses.
Dermatology
December 2024
Introduction: Chronic inflammatory dermatoses (CIDs) can significantly affect patients' lives. The Observatory of Chronic Inflammatory Skin Diseases (OMCCI) cohort was initiated to quantify the impact and disease evolution of four CID over 4 years' follow-up; at least 1,000 patients per CID are planned to be enrolled. The objective of this study was to present baseline characteristics of patients included in the OMCCI cohort between December 2020 and September 2022.
View Article and Find Full Text PDFPsoriasis is a common chronic skin disease, with well-characterised impact on quality-of life, however, no information is available on the lifetime impact of psoriasis on patients' lives. This descriptive cross-sectional web-based survey of patients with psoriasis, recruited from an online patient community, was conducted in France in 2021. Established questionnaires (Major Life-Changing Decision Profile-MLCDP, Dermatology Life Quality Index-DLQI, Hospital Anxiety and Depression Scale [HADS]), CAGE and BRIEF-COPE) were administered together with specially created questions.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigates the effectiveness of bimekizumab for treating palmoplantar pustulosis (PPP) and palmoplantar plaque psoriasis with pustules, conditions known to be difficult to manage due to their inflammatory nature.
- - In a case series involving 21 adults treated in France, bimekizumab demonstrated promising results, with 17 patients achieving complete skin clearance and significant improvements in symptoms after 1 to 4 months of treatment.
- - Outcomes also included assessments of joint pain and nail conditions, showing up to 70% improvement in nail involvement for a subset of patients, while treatment was well tolerated overall.
Impact of Baricitinib on Patients' Quality of Life after One Year of Treatment for Atopic Dermatitis in Real-World Practice: Results of the Observatory of Chronic Inflammatory Skin Diseases Registry.
Acta Derm Venereol
October 2023
The efficacy and safety of baricitinib for treatment of atopic dermatitis have been demonstrated in clinical trials; however, very few real-life studies have been published to date. The Observatory of Chronic Inflammatory Skin Diseases (OMCCI) registry was initiated to prospectively determine the long-term impairment caused by chronic inflammatory dermatoses on patients' lives. The study included 88 patients starting baricitinib for treatment of atopic dermatitis.
View Article and Find Full Text PDF